Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia

British Journal of Haematology

Volumn 135, Issue 4, 2006, Pages 475-485

  Rezvany, Mohammad Reza ^a,b   Tehrani, Mahmood Jeddi ^a,c   Karlsson, Claes ^a,d   Lundin, Jeanette ^a,d   Rabbani, Hodjattallah ^a   Österborg, Anders ^a,d   Mellstedt, Håkan ^a,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SEMNAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Avesina Research Institute   (Iran)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alemtuzumab; B cell chronic lymphocytic leukaemia; CD52; Clonality; T cells

Indexed keywords

ALEMTUZUMAB; CD4 ANTIGEN; CD8 ANTIGEN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMPLEMENTARITY DETERMINING REGION; COMPLEMENTARITY DETERMINING REGION 3; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HUMAN; IMMUNOTHERAPY; INJECTION SITE REACTION; MALE; MOLECULAR CLONING; PILOT STUDY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE RECEPTOR BV GENE; T LYMPHOCYTE RECEPTOR GENE;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMPLEMENTARITY DETERMINING REGIONS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENES, T-CELL RECEPTOR BETA; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, B-CELL, CHRONIC; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PILOT PROJECTS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTE SUBSETS;

EID: 33750091306     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06324.x     Document Type: Article

References (46)

1. Al-Harthi, L., Marchetti, G., Steffens, C.M., Poulin, J., Sekaly, R. & Landay, A. (2000) Detection of T-cell receptor circles (TRECs) as biomarkers for de novo T-cell synthesis using a quantitative polymerase chain reaction-enzyme linked immunosorbent assay (PCR-ELISA). Journal of Immunological Methods, 237, 187-197.
2. Caligaris-Cappio, F. (2003) Role of the microenvironment in chronic lymphocytic leukaemia. British Journal of Haematology, 123, 380-388.
3. Cavalli-Bjorkman, N., Osby, E., Lundin, J., Kalin, M., Osterborg, A. & Gruber, A. (2002) Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia. Medical Oncology, 19, 277-280.
4. Chomczynski, P. & Sacchi, N. (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry, 162, 156-159.
5. Davis, M.M. & Bjorkman, P.J. (1988) T-cell antigen receptor genes and T-cell recognition. Nature, 334, 395-402.
6. Davison, G.M., Novitzky, N., Kline, A., Thomas, V., Abrahams, L., Hale, G. & Waldmann, H. (2000) Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. Transplantation, 69, 1341-1347.
7. Farace, F., Orlanducci, F., Dietrich, P.Y., Gaudin, C., Angevin, E., Courtier, M.H., Bayle, C., Hercend, T. & Triebel, F. (1994) T-cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T-cell clonal expansions. Journal of Immunology, 153, 4281-4290.
8. Farace, F., Angevin, E., Poullion, I., Leboullaire, C., Ferir, G., Elias, D., Escudier, B. & Triebel, F. (1997) T-cell receptor CDR3 size distribution analysis to evaluate specific T-cell response to cancer vaccines. International Journal of Cancer, 71, 972-977.
9. Garcia, K.C., Degano, M., Stanfield, R.L., Brunmark, A., Jackson, M.R., Peterson, P.A., Teyton, L. & Wilson, I.A. (1996) An alphabeta T-cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science, 274, 209-219.
10. Gaschet, J., Denis, C., Milpied, N., Hallet, M.M., Romagne, F., Necker, A., Vivien, R., David-Ameline, J., Davodeau, F. & Bonneville, M. (1995) Alterations of T-cell repertoire after bone marrow transplantation: characterization of over-represented subsets. Bone Marrow Transplantation, 16, 427-435.
11. Gilleece, M.H. & Dexter, T.M. (1993) Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood, 82, 807-812.
12. Johnson, S., Smith, A.G., Loffler, H., Osby, E., Juliusson, G., Emmerich, B., Wyld, P.J. & Hiddemann, W. (1996) Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet, 347, 1432-1438.
13. Jorgensen, J.L., Esser, U., Fazekas de St Groth, B., Reay, P.A. & Davis, M.M. (1992) Mapping T-cell receptor-peptide contacts by variant peptide immunization of single-chain transgenics. Nature, 355, 224-230.
14. Karlsson C.N.S., Lundin J, Kimby E, Mellstedt H, Sander B, Porwit-Macdonald A. & Österborg, A. (2004) Alemtuzumab as first-line therapy in B-cell chronic lymphocytic leukemia (B-CLL): long-term follow-up of clinical effects, infectious complications and risk of Richter transformation (RT). The Hematology Journal, 5(Suppl. 2), S30 (abstr).
15. Keating, M.J., Flinn, I., Jain, V., Binet, J.L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B. & Rai, K.R. (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 99, 3554-3561.
16. Keating, M., Coutre, S., Rai, K., Osterborg, A., Faderl, S., Kennedy, B., Kipps, T., Bodey, G., Byrd, J.C., Rosen, S., Dearden, C., Dyer, M.J. & Hillmen, P. (2004) Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clinical Lymphoma, 4, 220-227.
17. Kiaii, S., Choudhury, A., Mozaffari, F., Rezvany, R., Lundin, J., Mellstedt, H. & Österborg, A. (2006) Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): the long-term effects of fludarabine and alemtuzumab treatment. Leukemia & Lymphoma, 47, 1229-1238.
18. Lundin, J. & Osterborg, A. (2004) Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia. Seminars in Hematology, 41, 234-245.
19. Lundin, J., Osterborg, A., Brittinger, G., Crowther, D., Dombret, H., Engert, A., Epenetos, A., Gisselbrecht, C., Huhn, D., Jaeger, U., Thomas, J., Marcus, R., Nissen, N., Poynton, C., Rankin, E., Stahel, R., Uppenkamp, M., Willemze, R. & Mellstedt, H. (1998) CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 16, 3257-3263.
20. Lundin, J., Kimby, E., Bjorkholm, M., Broliden, P.A., Celsing, F., Hjalmar, V., Mollgard, L., Rebello, P., Hale, G., Waldmann, H., Mellstedt, H. & Osterborg, A. (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, 100, 768-773.
21. Lundin, J., Porwit-MacDonald, A., Rossmann, E.D., Karlsson, C., Edman, P., Rezvany, M.R., Kimby, E., Osterborg, A. & Mellstedt, H. (2004) Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia, 18, 484-490.
22. Mackensen, A., Ferradini, L., Carcelain, G., Triebel, F., Faure, F., Viel, S. & Hercend, T. (1993) Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Research, 53, 3569-3573.
23. Mackensen, A., Veelken, H., Lahn, M., Wittnebel, S., Becker, D., Kohler, G., Kulmburg, P., Brennscheidt, U., Rosenthal, F., Franke, B., Mertelsmann, R. & Lindemann, A. (1997) Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts. Journal of Molecular Medicine, 75, 290-296.
24. Mellstedt, H. & Choudhury, A. (2006) T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. Cancer Immunology, Immunotherapy, 55, 210-220.
25. Montserrat, E. (2002) Current and developing chemotherapy for CLL. Medical Oncology, 19(Suppl.), S11-S19.
26. Osterborg, A., Fassas, A.S., Anagnostopoulos, A., Dyer, M.J., Catovsky, D. & Mellstedt, H. (1996) Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. British Journal of Haematology, 93, 151-153.
27. Osterborg, A., Dyer, M.J., Bunjes, D., Pangalis, G.A., Bastion, Y., Catovsky, D. & Mellstedt, H. (1997a) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 15, 1567-1574.
28. - T cells are induced in responding B-cell lymphoma patients treated with Campath-1H (anti-CD52). European Journal of Haematology, 58, 5-13.
29. Osterborg, A., Karlsson, C., Lundin, J., Kimby, E. & Mellstedt, H. (2006) Strategies in the management of alemtuzumab-related side effects. Seminars in Oncology, 33, S29-S35.
30. Pannetier, C., Cochet, M., Darche, S., Casrouge, A., Zoller, M. & Kourilsky, P. (1993) The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proceedings of the National Academy of Sciences of the United States of America, 90, 4319-4323.
31. Pearl, J.P., Parris, J., Hale, D.A., Hoffmann, S.C., Bernstein, W.B., McCoy, K.L., Swanson, S.J., Mannon, R.B., Roederer, M. & Kirk, A.D. (2005) Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. American Journal of Transplantation, 5, 465-474.
32. Perkins, J.G., Flynn, J.M., Howard, R.S. & Byrd, J.C. (2002) Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer, 94, 2033-2039.
33. Protheroe, A.S., Pickard, C., Johnson, P.W., Craddock, T., Shefta, J., Short, K., Lancaster, F., Selby, P.J., Henwood, J. & Boylston, A.W. (2000) Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue. British Journal of Haematology, 111, 766-773.
34. Rai, K.R., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G.A., Larson, R.A., Cheson, B.D. & Schiffer, C.A. (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. The New England Journal of Medicine, 343, 1750-1757.
35. Ravandi, F., Verma, A., Ridgeway, J. & Pursell, K. (2003) Chronic lymphocytic leukemia (B-CLL) occurring with human immunodeficiency virus (HIV) infection: implications. Leukemia Research, 27, 853-857.
36. Rezvany, M.R., Jeddi-Tehrani, M., Osterborg, A., Kimby, E., Wigzell, H. & Mellstedt, H. (1999) Oligoclonal TCR-BV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Blood, 94, 1063-1069.
37. Rezvany, M.R., Jeddi-Tehrani, M., Rabbani, H., Lewin, N., Avila-Carino, J., Osterborg, A., Wigzell, H. & Mellstedt, H. (2000) Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 111, 608-617.
38. Rezvany, M.R., Jeddi-Tehrani, M., Wigzell, H., Osterborg, A. & Mellstedt, H. (2003) Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia. Blood, 101, 1063-1070.
39. Sensi, M., Farina, C., Maccalli, C., Lupetti, R., Nicolini, G., Anichini, A., Parmiani, G. & Berd, D. (1997) Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. The Journal of Clinical Investigation, 99, 710-717.
40. Sensi, M., Farina, C., Maccalli, C., Anichini, A., Berd, D. & Parmiani, G. (1998) Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination. Journal of Immunotherapy, 21, 198-204.
41. Stockinger, B., Kassiotis, G. & Bourgeois, C. (2004) Homeostasis and T-cell regulation. Current Opinion in Immunology, 16, 775-779.
42. Storek, J., Witherspoon, R.P. & Storb, R. (1995) T-cell reconstitution after bone marrow transplantation into adult patients does not resemble T-cell development in early life. Bone Marrow Transplantation, 16, 413-425.
43. Sun, W., Nie, H., Li, N., Zang, Y.C., Zhang, D., Feng, G., Ni, L., Xu, R., Prasad, S., Robinson, R.R., Ho, W., Sercarz, E. & Zhang, J.Z. (2005) Skewed T-cell receptor BV14 and BV16 expression and shared CDR3 sequence and common sequence motifs in synovial T-cells of rheumatoid arthritis. Genes and Immunity, 6, 248-261.
44. + naive and memory T-cell subsets independently predicts course of disease in B-CLL. Journal of Clinical Oncology, 23(Suppl. 1), 581S (abstr).
45. Villers, D., Milpied, N., Gaschet, J., Davodeau, F., Hallet, M.M., Bonneville, M. & Vie, H. (1994) Alteration of the T-cell repertoire after bone marrow transplantation. Bone Marrow Transplantation, 13, 19-26.
46. Wendtner, C.M., Ritgen, M., Schweighofer, C.D., Fingerle-Rowson, G., Campe, H., Jager, G., Eichhorst, B., Busch, R., Diem, H., Engert, A., Stilgenbauer, S., Dohner, H., Kneba, M., Emmerich, B. & Hallek, M. (2004) Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia, 18, 1093-1101.